NSA Whistleblower: Page FISA Warrant Likely a Gateway to

New Post Public Reply Private Reply Replies (0) Message Board
Lmcat
220
NSA Whistleblower: Page FISA Warrant Likely a Gateway to Spy on Entire Trump Campaign
31 Mar 2019

The Obama-era FISA warrant obtained to monitor the communications of Carter Page was most likely utilized as a gateway to spy on the rest of Donald Trump’s 2016 presidential campaign, contended William Binney, a former highly placed NSA official turned whistleblower.

The same warrant against Page technically could also have been used to legally justify collecting data on the Republican National Committee (RNC) or the leadership of the Republican Party, Binney said.

Binney was an architect of the NSA’s surveillance program.
He became a famed whistleblower when he resigned on October 31, 2001 after spending more than 30 years with the agency.

He was speaking during an interview that aired Sunday on this reporter’s weekend talk radio show, “Aaron Klein Investigative Radio,” broadcast on New York’s AM 970 The Answer and NewsTalk 990 AM in Philadelphia.

Binney referred to measures put into place by President Obama in January 2014 that restrict the NSA to collecting data on individuals that are only two steps removed from a target being monitored. He explained that if Page had called anyone from the Trump campaign or the RNC, the NSA could legally have spied not only on that second individual but on others called by the second person.

Stated Binney: “If you get a warrant on say Carter Page and for example he has a call or an email to the Republican National Committee or anybody in the Trump campaign, that warrant then allows them to go out two degrees from the RNC to everybody associated with the RNC and from anyone from the Trump campaign to anyone they are associated with.”

“So effectively what that means is that they had the ability to basically spy on anybody,” he said. “They could spy on everybody on the Republican National Committee or everybody in the Trump campaign.”

“Not only could they collect all the data on that second person but all of the data content as well as metadata on anybody that he talks to,” Binney added.

In late October 2016, then-FBI director James Comey signed the first of three successful FISA applications to obtain warrants to spy on Page, the American financial consultant who was tangentially associated with the campaign as an adviser. The second and third were renewal applications since a FISA warrant must be renewed every 90 days.

All three applications reportedly cited as key evidence against Page the largely-discredited dossier produced by the controversial Fusion GPS firm which was paid for its anti-Trump work by Hillary Clinton’s 2016 campaign and the Democratic National Committee via the Perkins Coie law firm.

According to Republican House characterizations, the FISA applications signed by Comey withheld key information raising questions about the dossier, including that it was financed by Clinton and the DNC and had known credibility issues.

Binney argued that the warrant on Page was likely used to “legitimize” and “justify” spying on the entire Trump campaign.

“That’s why they want to hide the FISA request and all of the justification and affidavits that they filed to obtain it.”


https://www.breitbart.com/politics/2019/03/31...-campaign/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Rigel Pharmaceuticals Updates on Financials and Future Plans

Updated Category News Views 130

Rigel Pharmaceuticals' Business Update and 2025 Outlook Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a notable biotechnology company, recently provided a compelling business update, highlighting its financial performance and strategic ambitions for 2025. The report shared preliminary insights into the fourth quarter of 2024, showcasing substantial revenue streams from its...

Continue Reading
Grant Cardone Explores Future of Investments in Bitcoin and Real Estate

Updated Category News Views 409

Understanding Investment Shifts in Today's Economy Grant Cardone, a prominent real estate investor and entrepreneur known for his work with Cardone Capital, is keeping a keen eye on the fluctuations within the investment landscape. With approximately $7 trillion currently held in money markets, he questions where this substantial amount of cash will be allocated as...

Continue Reading
BlueNord ASA Secures Major Funding Through Hybrid Bond Issuance

Updated Category News Views 175

BlueNord ASA Successfully Places Hybrid Bond Issue BlueNord ASA (OSE: BNOR) has achieved a significant milestone in its financial strategy with the successful placement of a new subordinated callable hybrid bond issue worth USD 300 million. This bond matures in 2085, marking a robust step forward for the company. The first call on the hybrid bond is at 100% of nominal...

Continue Reading
Aehr Test Systems (NASDAQ: AEHR) Sees Growth in 2026 Amid Fluctuations

Updated Category News Views 133

Strong Start to 2026 for Aehr Test Systems For shares of Aehr Test Systems, the year 2026 has kicked off in a remarkable way. As of the latest market close, the stock has risen by 44%, showcasing significant investor enthusiasm. This surge follows a recent earnings release that, while presenting mixed signals, ultimately contributed to a 16% jump in the stock price the...

Continue Reading
Carlton Precious Enhances Community Relations and Expansion Plans

Updated Category News Views 151

Carlton Precious Inc. Strengthens Community Engagement TORONTO — Carlton Precious Inc. (TSX-V: CPI | OTCQB: NBRFF), a notable player in precious and base metals exploration, is excited to share significant developments regarding its Esquilache Silver project. The Company has successfully finalized an agreement with the local community of San Antonio de Esquilache, which...

Continue Reading